Detalles de la búsqueda
1.
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Am J Addict
; 29(4): 313-322, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32246728
2.
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
Alcohol Clin Exp Res
; 42(10): 2011-2021, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30055046
3.
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
CNS Spectr
; 23(4): 284-290, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28625204
4.
A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder.
Int J Eat Disord
; 46(3): 239-45, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23381803
5.
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Lancet
; 377(9776): 1506-13, 2011 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21529928
6.
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
Neuropsychopharmacology
; 47(3): 696-703, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887529
7.
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Alcohol Clin Exp Res
; 35(10): 1804-11, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21575016
8.
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Schizophr Res
; 232: 45-53, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34015555
9.
Acanthosis nigricans identifies youth at high risk for metabolic abnormalities.
J Pediatr
; 156(1): 87-92, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19796772
10.
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
J Clin Psychiatry
; 81(2)2020 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32141723
11.
Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Addiction
; 115(2): 239-246, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31313402
12.
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
J Clin Psychiatry
; 81(2)2020 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32160422
13.
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Am J Psychiatry
; 176(6): 457-467, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30845818
14.
Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Alcohol Clin Exp Res
; 32(3): 498-504, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18241321
15.
Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR inhaled insulin pharmacokinetics and glucodynamics.
Br J Clin Pharmacol
; 65(4): 480-7, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17922880
16.
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Addiction
; 113(8): 1477-1487, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29493836
17.
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
Schizophr Res
; 195: 245-251, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158012
18.
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Drug Alcohol Depend
; 187: 171-178, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674251
19.
Injectable extended-release naltrexone for opioid dependence.
Lancet
; 378(9792): 665; author reply 666, 2011 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21856477
20.
Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures.
Diabetes Technol Ther
; 9(1): 80-8, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17316102